Bio-Rad Laboratories anti-biotherapeutic and anti-MMAE antibodies

Bio-Rad Laboratories has launched four anti-idiotypic antibodies to the drugs atezolizumab (Lemtrada), avelumab (Bavencio), obinutuzumab (Gazyvaro) and ocrelizumab (Ocrevus), extending its range of anti-biotherapeutic antibodies. It has also introduced its anti-monomethyl auristatin E (MMAE) biotherapeutic antibody range for bioanalysis.

The company’s range of ready-made anti-biotherapeutic antibodies enables the development of robust bioanalytical assays against marketed biologic drugs. The anti-idiotypic antibodies are suitable for pharmacokinetic (PK) and antidrug-antibody assays for atezolizumab, avelumab, obinutuzumab and ocrelizumab, enabling therapeutic drug monitoring for innovator and biosimilar products.

The anti-MMAE antibody range supports bioanalysis of antibody-drug conjugates (ADCs) carrying MMAE as payload. MMAE is a potent antimitotic agent that inhibits cell division. Due to its toxicity, MMAE is not used as a drug itself, but instead forms the payload component of ADCs. The anti-MMAE biotherapeutic antibodies enable the development of sensitive assays for both ADCs incorporating the toxin and the toxin itself.